Brolucizumab  (Synonyms: DLX1008; ESBA 1008; RTH258)

Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (K_D=1.05 pM). Brolucizumab can be used for the research of cancer^[1][2].

Brolucizumab (2683 nM) inhibits VEGF-A112-induced phosphorylation of VEGFR1 in U87MG human glioma cells and of VEGFR2 in ZHE-483-2 GMEC^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Brolucizumab (15 mg/kg; i.p. 5 days per week for 21 or 41 days) slows the growth of mSLK-KSHV xenograft tumors^[2].
Brolucizumab (5-50 mg/kg; i.p. once or twice daily for 28 days) delays in vivo tumor growth in U87MG glioma models^[1].
Brolucizumab (10 mg/kg; i.v.) shows a half-life of 5.4-7.8 minutes for the rapid decline phase and 1.4-1.9 hours for the slow decline phase in mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1531589-13-5

[Brolucizumab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Szabó E, et, al. Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. J Pharmacol Exp Ther. 2018 May;365(2):422-429.  [Content Brief]

  [2]. Eason AB, et, al. DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma. PLoS One. 2020 May 14;15(5):e0233116.  [Content Brief]